Xiaozhe Li1, Beihui Huang1, Junru Liu1, Meilan Chen1, Jingli Gu1, Juan Li2. 1. Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. 2. Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. ljuan@mail.sysu.edu.cn.
Abstract
PURPOSE: To assess the feasibility and prognostic value of minimal residual disease (MRD) evaluated by multiparameter flow cytometry (MFC) in newly diagnosed amyloid light chain (AL) amyloidosis. METHODS: Clinical data from 25 consecutive newly diagnosed AL amyloidosis patients with MRD data tested at 3 months after first-line therapy completion were retrospectively analysed in a single centre from 2012 to 2019. First-line therapy included 8 courses of VD or 4 courses of VD plus sequential autologous stem cell transplantation (ASCT), both without maintenance therapy. RESULTS: Of 25 patients with very good partial response (VGPR) or better, 19 (76%) achieved MRD negativity. Baseline characteristics were not different between MRD-negative and MRD-positive patients. More ASCT patients than non-ASCT patients (90.0% vs 53.3%, p = 0.043) achieved MRD negativity. In the MRD-negative and MRD-positive groups, cardiac response was observed in 93% and 25% (p = 0.019) and any organ response in 94% and 50%, respectively (p = 0.023). At a median follow-up of 25.1 months, MRD-negative patients showed significantly longer progression-free survival (PFS) from diagnosis than MRD-positive patients (24.52 vs 76.39 months, p = 0.004). CONCLUSIONS: MRD negativity measured by MFC at 3 months after first-line therapy completion in patients with AL amyloidosis is measurable and associated with improved organ response rates and PFS over a long follow-up.
PURPOSE: To assess the feasibility and prognostic value of minimal residual disease (MRD) evaluated by multiparameter flow cytometry (MFC) in newly diagnosed amyloid light chain (AL) amyloidosis. METHODS: Clinical data from 25 consecutive newly diagnosed AL amyloidosis patients with MRD data tested at 3 months after first-line therapy completion were retrospectively analysed in a single centre from 2012 to 2019. First-line therapy included 8 courses of VD or 4 courses of VD plus sequential autologous stem cell transplantation (ASCT), both without maintenance therapy. RESULTS: Of 25 patients with very good partial response (VGPR) or better, 19 (76%) achieved MRD negativity. Baseline characteristics were not different between MRD-negative and MRD-positive patients. More ASCT patients than non-ASCT patients (90.0% vs 53.3%, p = 0.043) achieved MRD negativity. In the MRD-negative and MRD-positive groups, cardiac response was observed in 93% and 25% (p = 0.019) and any organ response in 94% and 50%, respectively (p = 0.023). At a median follow-up of 25.1 months, MRD-negative patients showed significantly longer progression-free survival (PFS) from diagnosis than MRD-positive patients (24.52 vs 76.39 months, p = 0.004). CONCLUSIONS: MRD negativity measured by MFC at 3 months after first-line therapy completion in patients with AL amyloidosis is measurable and associated with improved organ response rates and PFS over a long follow-up.
Authors: Giampaolo Merlini; Angela Dispenzieri; Vaishali Sanchorawala; Stefan O Schönland; Giovanni Palladini; Philip N Hawkins; Morie A Gertz Journal: Nat Rev Dis Primers Date: 2018-10-25 Impact factor: 52.329
Authors: Gregory P Kaufman; Angela Dispenzieri; Morie A Gertz; Martha Q Lacy; Francis K Buadi; Suzanne R Hayman; Nelson Leung; David Dingli; John A Lust; Yi Lin; Prashant Kapoor; Ronald S Go; Steven R Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar Journal: Am J Hematol Date: 2015-01-16 Impact factor: 10.047
Authors: Tobias Dittrich; Tilmann Bochtler; Christoph Kimmich; Natalia Becker; Anna Jauch; Hartmut Goldschmidt; Anthony D Ho; Ute Hegenbart; Stefan O Schönland Journal: Blood Date: 2017-05-26 Impact factor: 22.113
Authors: Michel Attal; Valerie Lauwers-Cances; Cyrille Hulin; Xavier Leleu; Denis Caillot; Martine Escoffre; Bertrand Arnulf; Margaret Macro; Karim Belhadj; Laurent Garderet; Murielle Roussel; Catherine Payen; Claire Mathiot; Jean P Fermand; Nathalie Meuleman; Sandrine Rollet; Michelle E Maglio; Andrea A Zeytoonjian; Edie A Weller; Nikhil Munshi; Kenneth C Anderson; Paul G Richardson; Thierry Facon; Hervé Avet-Loiseau; Jean-Luc Harousseau; Philippe Moreau Journal: N Engl J Med Date: 2017-04-06 Impact factor: 91.245
Authors: T Jelinek; R Bezdekova; M Zatopkova; L Burgos; M Simicek; T Sevcikova; B Paiva; R Hajek Journal: Blood Cancer J Date: 2018-01-19 Impact factor: 11.037
Authors: Efstathios Kastritis; Ioannis V Kostopoulos; Evangelos Terpos; Bruno Paiva; Despina Fotiou; Maria Gavriatopoulou; Nikolaos Kanellias; Dimitrios C Ziogas; Maria Roussou; Magdalini Migkou; Evangelos Eleutherakis-Papaiakovou; Ioannis P Trougakos; Ourania Tsitsilonis; Meletios A Dimopoulos Journal: Blood Cancer J Date: 2018-05-24 Impact factor: 11.037